TNXP stock gains on U.S. patent win for monkeypox vaccine technology (NASDAQ:TNXP)
seekingalpha.com
finance
2022-06-01 11:32:43

The shares of clinical-stage biotech Tonix Pharmaceuticals (NASDAQ:TNXP) surged ~34% in the pre-market Wednesday after the company announced that the U.S. regulators issued a patent covering the technology used in a monkeypox and smallpox vaccine candidate. The patent, entitled "Synthetic Chimeric Poxviruses," issued by the United States Patent and Trademark Office (USPTO) relates to claims for the company's synthetic horsepox virus, Tonix (TNXP) said. In addition to TNX-801vaccine candidate targeted at monkeypox and smallpox, synthetic horsepox virus forms the basis for the company's Recombinant Pox Virus (RPV) platform designed against microbes such as COVID-19.
